19:55 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

ViiV's two-drug HIV regimen meets again in Phase III

ViiV Healthcare Ltd. (Brentford, U.K.) said a once-monthly two-drug regimen comprising cabotegravir and Edurant rilpivirine met the primary endpoint in the Phase III FLAIR trial as maintenance treatment in HIV-1-infected, antiretroviral therapy-naïve patients who are...
17:24 , Aug 17, 2018 |  BC Week In Review  |  Clinical News

J&J, ViiV's two-drug regimen meets in Phase III for maintenance treatment of HIV-1 infection

ViiV Healthcare Ltd. (Brentford, U.K.) and Johnson & Johnson (NYSE:JNJ) said a two-drug regimen comprising cabotegravir and Edurant rilpivirine met the primary endpoint in the Phase III ATLAS trial as maintenance treatment in HIV-1-infected adults...
21:11 , Jan 23, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Other A gastric-resident method of delivering multiple antiretroviral (ART) agents together could treat HIV for prolonged periods with a single administration. The gastric-resident dosage form comprises six rigid arms allowing for the delivery of...
01:21 , Dec 30, 2016 |  BC Week In Review  |  Clinical News

Long-acting intramuscular cabotegravir: Ph III HPTN 083 started

ViiV began the 3-step, double-blind, international Phase III HPTN 083 trial to compare 600 mg long-acting intramuscular cabotegravir vs. once-daily oral Truvada tenofovir disoproxil fumarate/emtricitabine in 4,500 men and transgender women who have sex with...
16:15 , Nov 30, 2016 |  BC Week In Review  |  Clinical News

Cabotegravir: Ph III started

ViiV began the open-label, international Phase III FLAIR trial to evaluate switching to cabotegravir plus Edurant rilpivirine following a 20-week induction therapy with once-daily oral Triumeq dolutegravir/abacavir/lamivudine in about 600 treatment-naïve patients. After induction, patients...
16:15 , Nov 30, 2016 |  BC Week In Review  |  Clinical News

Cabotegravir: Ph III started

ViiV began the open-label, international Phase III ATLAS trial to evaluate switching to cabotegravir plus Edurant rilpivirine in about 570 patients who achieved viral suppression on a regimen of 2 nucleoside reverse transcriptase inhibitors (NRTIs)...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Company News

J&J, Viiv Healthcare deal

Johnson & Johnson’s Janssen Biotech Inc. unit partnered co-exclusively with ViiV to globally develop and commercialize a combination regimen of long-acting, injectable formulations of HIV infection therapies Edurant rilpivirine and cabotegravir. Edurant, a marketed small...
02:21 , Jan 8, 2016 |  BC Extra  |  Company News

J&J announces 22 partnerships

The Johnson & Johnson Innovation unit of Johnson & Johnson (NYSE:JNJ) unveiled 22 new collaborations spanning the cancer, diabetes, rare diseases and consumer healthcare sectors. The Innovation unit also said it will start an external...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

Edurant rilpivirine: Phase IIb data

The 96-week, open-label, international Phase IIb LATTE 2 trial in 286 evaluable patients with HIV-1 infection showed that a long-acting intramuscular regimen of cabotegravir plus rilpivirine given every 4 or 8 weeks as suppressive maintenance...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

Cabotegravir: Phase IIb data

The 96-week, open-label, international Phase IIb LATTE 2 trial in 286 evaluable patients with HIV-1 infection showed that a long-acting intramuscular regimen of cabotegravir plus rilpivirine given every 4 or 8 weeks as suppressive maintenance...